|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1991-10-22
|
|
pubmed:abstractText |
We determined the ability of the multidrug resistance (MDR) reversal agent cyclosporin-A to increase anthracycline drug accumulation in colorectal tumour cells in vitro, using the technique of on-line flow cytometry. Data of four previously untreated patients showed that cyclosporin-A can increase intracellular net-uptake of daunorubicin. A phase II study was initiated in 24 colorectal cancer patients. They received cyclosporin-A at a dose of 3 mg kg-1 over 1 h as i.v. infusion, at 7 h and at 1 h preceding cytotoxic drug administration. At the end of the second cyclosporin-A administration epidoxorubicin 90 mg m-2 was administered as i.v. bolus. Cycles were repeated every 3 weeks. Median cyclosporin-A peak blood levels and levels at 18 h after cytotoxic drug administration appeared to be 6248 ng ml-1 and 1012 ng ml-1 respectively. Only one partial response was observed, despite these high cyclosporin-A levels. Cyclosporin-A did not cause major toxicity, only a 29% incidence of hot flushes was observed. Epidoxorubicin toxicities were as expected but the frequency of severe leucocytopenia was striking. This treatment schedule can not be considered active in colorectal cancer.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/1892765-2164872,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1892765-2217530,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1892765-2372507,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1892765-2407810,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1892765-2477337,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1892765-2536292,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1892765-2562856,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1892765-2585018,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1892765-2706734,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1892765-2766891,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1892765-3040060,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1892765-3280741,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1892765-3288374,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1892765-3330530,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1892765-3365692,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1892765-3457471,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1892765-3553950,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1892765-3559654,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1892765-360064,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1892765-3741759,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1892765-6616450,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1892765-6753558,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1892765-6991095
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
64
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
361-4
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:1892765-Adult,
pubmed-meshheading:1892765-Aged,
pubmed-meshheading:1892765-Colorectal Neoplasms,
pubmed-meshheading:1892765-Cyclosporins,
pubmed-meshheading:1892765-Drug Resistance,
pubmed-meshheading:1892765-Epirubicin,
pubmed-meshheading:1892765-Female,
pubmed-meshheading:1892765-Flow Cytometry,
pubmed-meshheading:1892765-Humans,
pubmed-meshheading:1892765-Leukopenia,
pubmed-meshheading:1892765-Male,
pubmed-meshheading:1892765-Middle Aged
|
|
pubmed:year |
1991
|
|
pubmed:articleTitle |
A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance.
|
|
pubmed:affiliation |
Department of Medical Oncology, Rotterdam Cancer Institute/Daniel den Hoed Kliniek, The Netherlands.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
In Vitro,
Research Support, Non-U.S. Gov't
|
